0000000000943107

AUTHOR

Daniela Marino

showing 2 related works from this author

APOBEC4 Enhances the Replication of HIV-1

2016

APOBEC4 (A4) is a member of the AID/APOBEC family of cytidine deaminases. In this study we found a high mRNA expression of A4 in human testis. In contrast, there were only low levels of A4 mRNA detectable in 293T, HeLa, Jurkat or A3.01 cells. Ectopic expression of A4 in HeLa cells resulted in mostly cytoplasmic localization of the protein. To test whether A4 has antiviral activity similar to that of proteins of the APOBEC3 (A3) subfamily, A4 was co-expressed in 293T cells with wild type HIV-1 and HIV-1 luciferase reporter viruses. We found that A4 did not inhibit the replication of HIV-1 but instead enhanced the production of HIV-1 in a dose-dependent manner and seemed to act on the viral L…

RNA virusesMale0301 basic medicineMolecular biologylcsh:MedicineArtificial Gene Amplification and ExtensionCytidinePathology and Laboratory MedicineVirus ReplicationBiochemistryPolymerase Chain ReactionJurkat cellschemistry.chemical_compoundCytidine deaminationImmunodeficiency VirusesTranscription (biology)TestisMedicine and Health Scienceslcsh:SciencePromoter Regions GeneticMultidisciplinaryCytidineTransfectionEnzymesImmunoblot AnalysisMedical MicrobiologyDeaminationViral PathogensViruses293T cellsCell linesPathogensOxidoreductasesBiological culturesLuciferaseResearch ArticleMolecular Probe TechniquesDNA constructionBiologyMicrobiologyCell Line03 medical and health sciencesCytidine DeaminaseRetrovirusesHumansMicrobial PathogensHIV Long Terminal Repeat030102 biochemistry & molecular biologylcsh:RLentivirusHEK 293 cellsOrganismsBiology and Life SciencesHIVProteinsPromoterMolecular biologyResearch and analysis methodsMolecular biology techniques030104 developmental biologychemistryPlasmid ConstructionHIV-1Enzymologylcsh:QEctopic expressionCloningPLOS ONE
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct